An Open-label Extension Study to CQTI571A2102 to Evaluate the Long-term Safety, Tolerability and Efficacy of QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension
Phase of Trial: Phase III
Latest Information Update: 12 Aug 2015
Price : $35 *
At a glance
- Drugs Imatinib (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions; Registrational
- Sponsors Novartis
- 10 Jul 2015 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 06 Oct 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 21 Nov 2013 New trial record